NatureSelect.ai Secures $100M; Aulis Capital Launches $200M Fund

NatureSelect.ai Secures Significant Funding

NatureSelect.ai, a Shenzhen-based startup focused on AI emotional companions, has successfully raised over $100 million in financing. This comes as the company prepares for its product launch scheduled for this month.

Several prominent investors, including 5Y Capital, Qiming Venture Partners, SCV, iMPC, and HyT Capital, have supported this funding round.

Innovative Emotional Companion Products

Established in early 2024, NatureSelect.ai is dedicated to creating enduring human-AI relationships through advanced technology. Its flagship product, EVE, is a 3D AI companion that boasts long-term memory capabilities and can perform various real-world tasks. From ordering boba tea to delivering flowers, EVE integrates seamlessly into the daily lives of users.

Additionally, NatureSelect.ai is working on Elys, a groundbreaking agentic social network where user interactions create contextual memories. This platform aims to provide personalized AI avatars that can deliver valuable insights, foster meaningful connections, and introduce users to new experiences.

Since launching Elys in private beta in February, the team has focused on refining its multi-user social memory system while prioritizing user privacy and enhancing connection efficiency. The current invite-only beta version of Elys is expected to transition to its official launch soon.

Aulis Capital Makes Its Mark with New Fund

Aulis Capital, spearheaded by former Qiming managing partner Nisa Leung, recently announced the closing of its inaugural fund, Aulis Capital Fund I, L.P., with total commitments reaching $200 million.

Founded in October 2025, Aulis Capital zeroes in on early- and growth-stage ventures in the life sciences and healthcare fields. The firm is dedicated to investing in transformative technologies that aim to enhance patient outcomes and drive medical innovation.

In a LinkedIn post, Leung emphasized her long-held belief in the significance of merging biopharma with capital discipline to improve global health. With the launch of Aulis Fund I, she aims to collaborate with top-tier operators, investors, and innovators to create groundbreaking healthcare solutions.

Expanding Horizons in Healthcare

Operating out of key locations, including Hong Kong, Beijing, Shanghai, Silicon Valley, and Boston, Aulis Capital is keen on supporting startups in the healthcare sector that are pioneering innovative drugs along with digital and AI-driven solutions.

In January 2026, Aulis Capital announced its involvement in a $107 million Series B funding round for US-based EpiBiologics, aimed at advancing the company's next-generation protein degradation platform for targeting extracellular membrane and soluble proteins.

The establishment of Aulis Capital marks a new journey for Leung, who transitioned from Qiming in February 2025 after nearly two decades. At Qiming, she was instrumental in founding and leading their healthcare practice, overseeing investments in notable firms such as Gan & Lee Pharmaceuticals, Zai Lab, CanSino Biologics, and Insilico Medicine.